Advocacy intelligence hub — real-time data for patient organizations
⚡ Live Alerts
Ionis Pharmaceuticals, Inc. — PHASE3
Takeda
Takeda
Takeda
Takeda — NA
ADARx Pharmaceuticals, Inc. — PHASE3
Cardiovascular and Interventional Radiological Society of Europe
Takeda — NA
Pharvaris Netherlands B.V. — PHASE3
Astria Therapeutics, Inc. — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Available/year
Foundation grants
Travel grants
Foundation Grants6
Good Days — Hereditary angioedema
Good Days
HealthWell Foundation — Hereditary angioedema
HealthWell Foundation
NORD Patient Assistance — Hereditary angioedema
NORD Patient Assistance
Patient Services Inc — Hereditary angioedema
Patient Services Inc
PAN Foundation — Hereditary angioedema
PAN Foundation
The Assistance Fund — Hereditary angioedema
The Assistance Fund
Patient Assistance Programs10
Haegarda
CSL Behring LLC
Kalbitor
Takeda Pharmaceuticals America, Inc.
SAJAZIR
Cycle Pharmaceuticals Ltd-Uk
EKTERLY
KalVista Pharmaceuticals Ltd
Danazol
Chartwell RX, LLC.
ANDEMBRY
CSL
Orladeyo
BioCryst Pharmaceuticals, Inc.
ICATIBANT
Bryant Ranch Prepack
TAKHZYRO
Takeda Pharmaceuticals America, Inc.
Ruconest
Pharming Healthcare Inc.
Travel Grants3
SAJAZIR
(ICATIBANT)Orphan drugstandardCycle Pharmaceuticals Ltd-Uk
EKTERLY
(SEBETRALSTAT)Orphan drugstandardKalVista Pharmaceuticals Ltd
Ruconest
(C1 ESTERASE INHIBITOR RECOMBINANT)Orphan drugstandardPharming Healthcare Inc.
Kalbitor
(ECALLANTIDE)Orphan drugstandardTakeda Pharmaceuticals America, Inc.
Haegarda
(C1 esterase inhibitor subcutaneous (human))Orphan drugstandardCSL Behring LLC
ANDEMBRY
(GARADACIMAB)Orphan drugstandardCSL
Orladeyo
(berotralstat)Orphan drugstandardBioCryst Pharmaceuticals, Inc.
12.1 Mechanism of Action Berotralstat is a plasma kallikrein inhibitor that binds to plasma kallikrein and inhibits its proteolytic activity. Plasma k...
TAKHZYRO
(LANADELUMAB-FLYO)Orphan drugstandardTakeda Pharmaceuticals America, Inc.
Mast cell mediators in hereditary angioedema.
Mast cell mediators in hereditary angioedema.
Eosinophilic inflammation in hereditary angioedema: a single-center real-world retrospective chart review study.
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent, unpredictable swelling attacks primarily driven by bradykinin-mediated vascular permeability. However, additional inf...
Updates in hereditary angioedema and chronic spontaneous urticaria.
Hereditary angioedema (HAE) is a genetic disorder caused by either deficiency of C1 esterase inhibitor (85% of cases) or normal to high levels of nonfunctional C1 esterase inhibitor. Both defects lead...
Hereditary Angioedema.
Hereditary angioedema is a rare and disabling disorder caused by mutations in the SERPING1 gene. These mutations ultimately lead to deficient or dysfunctional C1 esterase inhibitor and unregulated act...
Rethinking the management of hereditary angioedema.
Background: Hereditary angioedema with C1INH deficiency (HAE-C1INH) is a rare, debilitating genetic disorder characterized by recurrent, unpredictable attacks. Although treatments exist, patients with...
Epidemiological and clinical characteristics of hereditary angioedema in the Baltic states.
Hereditary angioedema (HAE) is a rare, potentially life-threatening disorder characterised by recurrent episodes of localised oedema caused by bradykinin overproduction. Accurate epidemiological data ...
Laurence Bouillet, Professor
Grenoble Hospital University
📍 Grenoble
Global Clinical Program Director
CSL Behring
Henry Li, MD
Institute For Asthma & Allergy
📍 Wheaton, Maryland
Lauge Farnaes, MD
ADARx Pharmaceuticals, Inc.
📍 Little Rock, Arkansas
Jolanta Bernatoniene, MD
Investigative Site #1
📍 Vienna, Ontario
Michael Osthoff, PD Dr. med.
University Hospital Basel, Division of Internal Medicine